Stock Details
DSKYF is Daiichi Sankyo Company, Limited's stock. Stock exchange Other OTC (Currency USD). Average price in 50 days is 24.62$. Average daily volumn in 3 months 4.4k. Market cap 42.95B



Stock symbol : DSKYF. Exchange : Other OTC. Currency : USD
Lastest price : 24.74$. Total volume : 143.60k. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Daiichi Sankyo Company, Limited (DSKYF)
Last Price
24.74$
Change
0.29
Volume
143.60k

Previous Close24.45
Open24.37
Day Range24.22-24.74
Bid0.00 x N/A
Ask0.00 x N/A
Volume143.6k
Average Volume4.4k
Market Cap42.95B
Beta0.75
52 Week Range17.61-28.93
Trailing P/E66.86
Foward P/E65.11
Dividend (Yield %)0.85%
Ex-Dividend Date2022-09-29



Financial Details


According to Daiichi Sankyo Company, Limited's financial reports the company's revenue in 2022 were 1.04T an decrease( +3.95%) over the years 2021 revenue that were of 962.52B. In 2022 the company's total earnings were 66.97B while total earnings in 2021 were 75.96B(-12%).


Loading ...



Organization

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatm... ent; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

Market Cap:
42.95B
Revenue:
1.04T
Total Assets:
2.22T
Total Cash:
662.48B


News about "Daiichi Sankyo Company, Limited"

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Large Decline in Short Interest

Source from : Defense World - 8 days ago

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY โ€“ Get Rating) was the recipient of a large decline in short interest in May. As of May 31st, there was short interest totalling 105,100 shares, a decline ...See details»


Daiichi Sankyo Co. Ltd.

Source from : Wall Street Journal - 8 days ago

1 Day 4568 -1.51% DJIA 0.26% S&P 500 0.57% Health Care/Life Sciences 0.47% Sunao Manabe President, CEO & Representative Director Daiichi Sankyo Co., Ltd. Hiroyuki Okuzawa CFO, Director ...See details»


Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Short Interest Down 57.6% in May

Source from : ETF Daily News - 29 days ago

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY โ€“ Get Rating) saw a significant decline in short interest in the month of May. As of May 15th, there was short interest totalling 125,000 shares ...See details»


DSKYF Daiichi Sankyo Company, Limited

Source from : Seeking Alpha - 1 month ago

**NM signifies a non meaningful value. A dash signifies the data is not available.See details»


japans-five-hottest-biotech-companies-in-healthcare-image

Japanโ€™s five hottest biotech companies in healthcare

Source from : the Top 10 - 10 days ago

While historically lacking in foreign investments, Japanโ€™s biotech scene is now thriving with global investors showing increasing interest. Here are five of the hottest Japanese private companies ...See details»


Daiichi Sankyo, AstraZeneca Begin Phase III Trial of Datopotamab Deruxtecan for TNBC

Source from : precisiononcologynews - 12 days ago

TROP2 antibody-drug conjugate versus chemo for previously untreated TNBC patients who aren't eligible for checkpoint inhibitors.See details»


Daiichi Sankyo Aims for Vanflyta Approvals in FLT3-ITD AML Outside of Japan

Source from : precisiononcologynews - 11 days ago

The firm will submit data from a Phase III trial, in which the drug plus chemotherapy reduced the risk of death by 22.4 percent compared to just chemo.See details»


daiichi-sankyo-phase-iii-quizartinib-trial-reports-positive-aml-data-image

Daiichi Sankyo Phase III quizartinib trial reports positive AML data

Source from : Clinical Trials Arena - 12 days ago

Daiichi Sankyo reported Phase III trial data, where quizartinib plus chemotherapy offered improvement in overall survival in AML patients.See details»


EHA: Survival data sets Daiichi Sankyoโ€™s quizartinib back on track

Source from : pharmaphorum - 12 days ago

Three years after Daiichi Sankyoโ€™s FLR3 inhibitor quizartinib ... Sales of Novartisโ€™ drug are too small to get their own line in the companyโ€™s quarterly results statements, but have been ...See details»


Daiichi Sankyo doses first person in breast cancer treatment trial

Source from : London South East - 12 days ago

(Alliance News) - Daiichi Sankyo Co Ltd on Monday said it dosed the first patient in the Tropion-Breast02 phase three trial, evaluating the safety and efficacy of datopotamab deruxtecan in ...See details»


ascletis-announces-appointment-of-mr-john-p-gargiulo-former-north-america-president-and-ceo-of-daiichi-sankyo-as-chief-business-officer-image

Ascletis Announces Appointment of Mr. John P. Gargiulo, Former North America President and CEO of Daiichi Sankyo, as Chief Business Officer

Source from : WFMZ-TV - 13 days ago

HANGZHOU, China and SHAOXING, China, June 12, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), today announces the expansion of management team with appointment of Mr. John P.See details»


NCLAT stays insolvency proceedings against RHC Holding

Source from : The Financial Express - 19 days ago

According to the Japanese company, the applicant along ... proceedings initiated by the Religare Comtrade Ltd, were also stayed, as per Daiichi Sankyo. โ€œIt is submitted that the Section 7 ...See details»


This Cancer Drug's News Could Mean Another Blockbuster for AstraZeneca

Source from : The Motley Fool - 11 days ago

Enhertu is a cancer drug that AstraZeneca is developing and commercializing in partnership with Japanese drug manufacturer Daiichi Sankyo ... earlier this month, the company unveiled some ...See details»


roquefort-therapeutics-buys-uk-biotech-in-return-for-shares-image

Roquefort Therapeutics buys UK biotech in return for shares

Source from : the Top 10 - 3 days ago

Medical biotechnology company, Roquefort Therapeutics, has conditionally agreed to buy UK biotech Oncogeni Ltd in return for shares.See details»